Henry Schein Analyst Ratings
Barrington Research Maintains Outperform on Henry Schein, Maintains $92 Price Target
Maintained OUTPERFORM Rating for Henry Schein Amidst Recovery and Growth Prospects
Henry Schein Analyst Ratings
Henry Schein Analyst Ratings
Barrington Research Maintains Outperform on Henry Schein, Raises Price Target to $92
UBS Adjusts Price Target on Henry Schein to $80 From $82, Maintains Neutral Rating
Henry Schein Analyst Ratings
UBS Maintains Neutral on Henry Schein, Lowers Price Target to $80
Analysts Have Conflicting Sentiments on These Healthcare Companies: Henry Schein (HSIC) and Esperion (ESPR)
Barrington Ups Price Target on Henry Schein to $92 From $90, Maintains Outperform Rating
Goldman Sachs Adjusts Price Target on Henry Schein to $74 From $76
Baird Adjusts Price Target on Henry Schein to $81 From $83, Maintains Neutral Rating
Henry Schein Sell Rating Affirmed Amidst Cybersecurity Woes and Execution Risks
Henry Schein: Strong Q1 Earnings but Uncertain Outlook Warrants Hold Rating
Goldman Sachs Sticks to Their Hold Rating for Henry Schein (HSIC)
Leerink Partners Adjusts Henry Schein's Price Target to $77 From $82, Keeps Market Perform Rating
Henry Schein Analyst Ratings
Jefferies Maintains Hold on Henry Schein, Raises Price Target to $81
Barrington Boosts Price Target on Henry Schein to $90 From $82, Keeps Outperform Rating